Restoring One Enzyme Cut Fat, Inflammation and Scarring in the Livers of Mice
A Cedars-Sinai-led team found that the enzyme UBE2N drops in liver cells as fatty liver disease turns into MASH, and that bringing it back to normal levels in mice reduced fat buildup, inflammation and scarring. The work is preclinical.

An enzyme called UBE2N falls in liver cells as fatty liver disease gets worse, and restoring it to normal levels in mice reduced fat buildup, inflammation and scarring, according to Cedars-Sinai. The multicenter study, co-led by Ekihiro Seki of Cedars-Sinai and published in Nature Metabolism, was done in mice and in human and mouse liver cells. No patient has been treated.
One in five to one in four patients moves on to MASH
Metabolic dysfunction-associated steatotic liver disease, or MASLD, used to be called nonalcoholic fatty liver disease. An estimated 100 million people in the United States have it, Cedars-Sinai said, citing the American Liver Foundation.
About 20% to 25% of them progress to MASH (metabolic dysfunction-associated steatohepatitis), the aggressive form in which fat in the liver leads to inflammation, cell damage and scarring, and which can progress toward liver failure. There is no cure for MASH, and care centers on lifestyle changes and protecting the liver from further damage.
Drug options are recent and few. The U.S. Food and Drug Administration approved the first medicine for liver scarring caused by the disease, resmetirom (sold as Rezdiffra), in March 2024, the agency said at the time. It was an accelerated approval based on 12-month results from a trial of 888 people. After a year, 24% to 36% of patients on the higher dose had their MASH resolve without worse scarring, compared with 9% to 13% on placebo.
The enzyme helps liver cells clear out damaged mitochondria
Earlier research had pointed to damaged mitochondria, the structures that power cells, as one driver of MASH. Healthy cells remove broken mitochondria through a cleanup process called mitophagy.
According to the paper's abstract, UBE2N is switched down in liver cells with MASH in both humans and mice. When the researchers removed the enzyme from mouse liver cells and fed the animals a Western-style diet, MASH and scarring got worse. Damaged mitochondria were cleared less well, and a protein called p62 built up inside the cells, setting off a form of inflammatory cell death. When the team raised UBE2N instead, the damage reversed and the liver returned toward normal.
“The UBE2N enzyme appears to protect the liver from the inflammation and damage associated with MASH by helping remove damaged mitochondria and supporting the breakdown of fat.” — Ekihiro Seki, MD, PhD, professor of medicine and biomedical sciences, Cedars-Sinai
"When levels of the enzyme fell, we saw more damaged cells and injury to the liver," Seki said. Deleting p62 as well softened the damage caused by losing UBE2N, which the authors read as evidence that the protein's buildup drives the disease forward.
A possible drug target, years away from patients
The authors describe p62 as a "proof-of-concept target" for treating MASH and fibrosis. That is a starting point for drug developers, not a treatment: the study did not test any medicine, and none of the findings has yet been checked in patients.
Shelly Lu, director of the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai, said future studies can test whether enhancing the pathway "can complement existing treatments, identify patients most likely to benefit and lead to new therapeutic approaches for preventing advanced disease." For metabolic disease, lifestyle remains the first line of treatment; in a trial in England and Canada, a diet and exercise program put young adults with early-onset type 2 diabetes into remission.
The paper went online in Nature Metabolism on 4 September. The work was funded by the U.S. National Institutes of Health, the National Research Foundation of Korea, the National Natural Science Foundation of China and the American Association for the Study of Liver Diseases, among others.
Not medical advice. This article reports on research and health programs for general information. Results from early studies often change in larger trials. Talk to a doctor before making decisions about your own health or treatment.
Sources
- Cedars-Sinai · cedars-sinai.org
- fda.gov
How we choose and verify sources: editorial policy.










